Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 2Phase 2 2Phase 3 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Peripheral Nervous System Diseases 1Gastrointestinal Neoplasms 1Cognitive Dysfunction 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Interventional × Silymarin × Clear all
NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown
56 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

NCT01829178 2015-05-13

Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

Tehran University of Medical Sciences

Phase 2/3 Completed
30 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡